Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025
Rhea-AI Summary
Rein Therapeutics (NASDAQ: RNTX) announced upcoming presentations at the IPF Summit 2025 in Boston, MA, from August 19-21, 2025. Chief Scientific Officer Cory Hogaboam will present on the role of lung-resident macrophages in IPF and the potential of Caveolin-scaffolding domain (CSD) peptides in treating the disease.
CEO Brian Windsor will discuss the company's Phase 2 trial of LTI-03, which will enroll up to 120 patients to evaluate safety, tolerability, and lung function outcomes. The trial represents Rein's innovative approach to addressing IPF through a multi-pathway strategy aimed at not just slowing fibrosis but potentially improving patient outcomes.
Positive
- None.
Negative
- None.
News Market Reaction – RNTX
In the Aug 15 session, RNTX gained 3.38%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that Chief Scientific Officer, Cory Hogaboam, and Chief Executive Officer, Brian Windsor, will each present at the IPF Summit 2025, taking place August 19-21, 2025, in Boston, MA.
Dr. Hogaboam will present at 8:00 am on Tuesday in a workshop titled, “Decoding the Disruptions in Natural Biological Processes to Advance Early Intervention in IPF – Unravelling the Molecular Biology of Immune Cells & Inflammation.” He will discuss:
- The role of key immune cells in idiopathic pulmonary fibrosis (IPF) called lung-resident macrophages.
- How macrophage modulation may be critical to stopping the disease from getting worse.
- How Caveolin-scaffolding domain (CSD) peptides, the class of molecules Rein is advancing, target multiple drivers of fibrosis and could potentially help repair lung tissue.
Dr. Windsor’s presentation, “Innovating Clinical Trial Design in IPF: Lessons from LTI-03,” will take place at 9:30 am on Thursday. He will provide:
- An overview of Rein’s Phase 2 trial of LTI-03, which will enroll up to 120 patients, assess safety and tolerability, and focus on lung function as a key outcome.
- A discussion of trial design, strategies around patient recruitment, and how Rein is working to make the study feasible and relevant in a fast-changing treatment landscape.
Dr. Windsor commented, “IPF remains a devastating and complex disease with significant unmet need. Our mission is not just to slow fibrosis, it’s to give patients a real chance to improve. We believe our multi-pathway approach offers something fundamentally different.”
The IPF Summit 2025 is a leading global event focused on advancing treatments for this deadly lung disease. It brings together leading scientists, clinicians, industry executives, and patient advocates to share advancements in the understanding and treatment of IPF and related interstitial lung diseases.
About Rein Therapeutics
Rein Therapeutics is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 has received Orphan Drug Designation in the U.S. and is in clinical development. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.S.
Forward-Looking Statements
This press release may contain forward-looking statements of Rein Therapeutics, Inc. ("Rein", the "Company", "we", "our" or "us") within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to future expectations, plans and prospects for Rein. We use words such as "anticipate," "believe," "estimate," "expect," "hope," "intend," "may," "plan," "predict," "project," "target," "potential," "would," "can," "could," "should," "continue," and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as well as the risks and uncertainties discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which is on file with the United States Securities and Exchange Commission (the "SEC") and in subsequent filings that the Company files with the SEC. These forward-looking statements should not be relied upon as representing the Company's view as of any date after the date of this press release, and we expressly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Rein Investor Relations & Media Contact:
Investor Relations
IR@ReinTx.com
